临床中的肿瘤异质性。
Tumour heterogeneity in the clinic.
机构信息
Princess Margaret Cancer Centre, University Health Network, Division of Medical Oncology and Hematology, Toronto, Ontario, Canada.
出版信息
Nature. 2013 Sep 19;501(7467):355-64. doi: 10.1038/nature12627.
Abstract
Recent therapeutic advances in oncology have been driven by the identification of tumour genotype variations between patients, called interpatient heterogeneity, that predict the response of patients to targeted treatments. Subpopulations of cancer cells with unique genomes in the same patient may exist across different geographical regions of a tumour or evolve over time, called intratumour heterogeneity. Sequencing technologies can be used to characterize intratumour heterogeneity at diagnosis, monitor clonal dynamics during treatment and identify the emergence of clinical resistance during disease progression. Genetic interpatient and intratumour heterogeneity can pose challenges for the design of clinical trials that use these data.
摘要
近年来，肿瘤学领域的治疗进展得益于对肿瘤患者之间的肿瘤基因型变异的识别，这些变异被称为患者间异质性，可预测患者对靶向治疗的反应。同一患者的肿瘤不同区域可能存在具有独特基因组的癌细胞亚群，或者随时间推移而进化，这被称为肿瘤内异质性。测序技术可用于在诊断时描述肿瘤内异质性，监测治疗期间的克隆动力学，并在疾病进展过程中识别临床耐药性的出现。遗传的患者间和肿瘤内异质性给使用这些数据的临床试验设计带来了挑战。
相似文献
1
Tumour heterogeneity in the clinic.
Nature. 2013 Sep 19;501(7467):355-64. doi: 10.1038/nature12627.
2
Tumour heterogeneity and immune-modulation.
Curr Opin Pharmacol. 2013 Aug;13(4):497-503. doi: 10.1016/j.coph.2013.04.006. Epub 2013 May 7.
3
Tumour heterogeneity.
Nature. 2013 Sep 19;501(7467):327. doi: 10.1038/501327a.
4
Selection and adaptation during metastatic cancer progression.
Nature. 2013 Sep 19;501(7467):365-72. doi: 10.1038/nature12628.
5
The challenge of intratumour heterogeneity in precision medicine.
J Intern Med. 2014 Jul;276(1):41-51. doi: 10.1111/joim.12240.
6
Tumour heterogeneity and resistance to cancer therapies.
Nat Rev Clin Oncol. 2018 Feb;15(2):81-94. doi: 10.1038/nrclinonc.2017.166. Epub 2017 Nov 8.
7
The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome.
BMC Med. 2017 Jul 18;15(1):133. doi: 10.1186/s12916-017-0900-y.
8
Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group.
Eur J Cancer. 2018 Apr;93:69-78. doi: 10.1016/j.ejca.2018.01.064. Epub 2018 Mar 20.
9
Tumour heterogeneity: principles and practical consequences.
Virchows Arch. 2016 Oct;469(4):371-84. doi: 10.1007/s00428-016-1987-9. Epub 2016 Jul 13.
10
Constraints in cancer evolution.
Biochem Soc Trans. 2017 Feb 8;45(1):1-13. doi: 10.1042/BST20160229.
引用本文的文献
1
Dissecting Tumor Heterogeneity by Liquid Biopsy-A Comparative Analysis of Post-Mortem Tissue and Pre-Mortem Liquid Biopsies in Solid Neoplasias.
Int J Mol Sci. 2025 Aug 6;26(15):7614. doi: 10.3390/ijms26157614.
2
Liquid biopsy in breast cancer: Redefining precision medicine.
J Liq Biopsy. 2025 Jul 16;9:100312. doi: 10.1016/j.jlb.2025.100312. eCollection 2025 Sep.
3
Bioprinted Organoids: An Innovative Engine in Biomedicine.
Adv Sci (Weinh). 2025 Sep;12(33):e07317. doi: 10.1002/advs.202507317. Epub 2025 Jul 25.
4
Deciphering Breast Tumor Heterogeneity Through Patient-Derived Organoids and Circulating Tumor Cells.
J Pers Med. 2025 Jun 25;15(7):271. doi: 10.3390/jpm15070271.
5
Combined cancer immunotherapy with lipid nanoparticle delivery of oligo-based cGAS-agonistic adjuvant and peptide or mRNA vaccines.
Mol Ther Nucleic Acids. 2025 Jul 1;36(3):102623. doi: 10.1016/j.omtn.2025.102623. eCollection 2025 Sep 9.
6
Tumor organoids in immunotherapy: from disease modeling to translational research.
J Immunother Cancer. 2025 Jul 15;13(7):e011733. doi: 10.1136/jitc-2025-011733.
7
Novel Lysosomal-Associated Transmembrane Protein 4B-Positive Stem-Like Cell Subpopulation Characterizes High-Risk Colorectal Cancer Subtypes.
MedComm (2020). 2025 Jul 13;6(7):e70284. doi: 10.1002/mco2.70284. eCollection 2025 Jul.
8
In vitro 3D drug sensitivity testing for patient-derived tumor-like cell clusters and whole-exome sequencing to personalize postoperative treatment: A study protocol for a multicenter randomized controlled trial.
PLoS One. 2025 Jul 14;20(7):e0326760. doi: 10.1371/journal.pone.0326760. eCollection 2025.
9
Prospective Isolation According to Melanin Pigment Content of Melanoma Cells With Heterogeneous Potentials for Disease Propagation.
Pigment Cell Melanoma Res. 2025 Jul;38(4):e70011. doi: 10.1111/pcmr.70011.
10
Updates on Liquid Biopsy and ctDNA in Transplant Oncology.
Cancers (Basel). 2025 Jun 10;17(12):1930. doi: 10.3390/cancers17121930.
本文引用的文献
1
Designing transformative clinical trials in the cancer genome era.
J Clin Oncol. 2013 May 20;31(15):1834-41. doi: 10.1200/JCO.2012.45.3639. Epub 2013 Apr 15.
2
Personalizing oncology: perspectives and prospects.
J Clin Oncol. 2013 May 20;31(15):1904-11. doi: 10.1200/JCO.2012.45.3605. Epub 2013 Apr 15.
3
Genome evolution during progression to breast cancer.
Genome Res. 2013 Jul;23(7):1097-108. doi: 10.1101/gr.151670.112. Epub 2013 Apr 8.
4
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.
Nature. 2013 May 2;497(7447):108-12. doi: 10.1038/nature12065. Epub 2013 Apr 7.
5
Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology.
Exp Mol Pathol. 2013 Aug;95(1):74-82. doi: 10.1016/j.yexmp.2013.01.004. Epub 2013 Mar 22.
6
Analysis of circulating tumor DNA to monitor metastatic breast cancer.
N Engl J Med. 2013 Mar 28;368(13):1199-209. doi: 10.1056/NEJMoa1213261. Epub 2013 Mar 13.
7
The implications of clonal genome evolution for cancer medicine.
N Engl J Med. 2013 Feb 28;368(9):842-51. doi: 10.1056/NEJMra1204892.
8
Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer.
PLoS One. 2013;8(2):e54170. doi: 10.1371/journal.pone.0054170. Epub 2013 Feb 13.
9
Comparison and validation of genomic predictors for anticancer drug sensitivity.
J Am Med Inform Assoc. 2013 Jul-Aug;20(4):597-602. doi: 10.1136/amiajnl-2012-001442. Epub 2013 Jan 26.
10
Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.
Sci Transl Med. 2013 Jan 9;5(167):167ra4. doi: 10.1126/scitranslmed.3004952.
Zotero 插件